Stage, Grade and Behavior of Bladder Urothelial Carcinoma Defined by the MicroRNA Expression Profile

Imagem de Miniatura
Arquivos
art_DIP_Stage_Grade_and_Behavior_of_Bladder_Urothelial_Carcinoma_2012_eng.pdf (1.22 MB)
Citações na Scopus
39
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
Citação
JOURNAL OF UROLOGY, v.188, n.5, p.1951-1956, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose: We identified miRNA expression profiles in urothelial carcinoma that are associated with grade, stage, and recurrence-free and disease specific survival. Materials and Methods: The expression of 14 miRNAs was evaluated by quantitative reverse transcriptase-polymerase chain reaction in surgical specimens from 30 patients with low grade, noninvasive (pTa) and 30 with high grade, invasive (pT2-3) urothelial carcinoma. Controls were normal bladder tissue from 5 patients who underwent surgical treatment for benign prostatic hyperplasia. Endogenous controls were RNU-43 and RNU-48. miRNA profiles were compared and Kaplan-Meier curves were constructed to analyze disease-free and disease specific survival. Results: miR-100 was under expressed in 100% of low grade pTa specimens (p <0.001) and miR-10a was over expressed in 73.3% (p <0.001). miR-21 and miR-205 were over expressed in high grade pT2-3 disease (p = 0.02 and <0.001, respectively). The other miRNAs were present at levels similar to those of normal bladder tissue or under expressed in each tumor group. miR-21 over expression (greater than 1.08) was related to shorter disease-free survival in patients with low grade pTa urothelial carcinoma. Higher miR-10a levels (greater than 2.30) were associated with shorter disease-free and disease specific survival in patients with high grade pT2-3 urothelial carcinoma. Conclusions: Four miRNAs were differentially expressed in the 2 urothelial carcinoma groups. miR-100 and miR-10a showed under expression and over expression, respectively, in low grade pTa tumors. miR-21 and miR-205 were over expressed in pT2-3 disease. In addition, miR-10a and miR-21 over expression was associated with shorter disease-free and disease specific survival. miRNAs could be incorporated into the urothelial carcinoma molecular pathway. These miRNAs could also serve as new diagnostic or prognostic markers and new target drugs.
Palavras-chave
urinary bladder, urothelium, carcinoma, microRNAs, biological markers
URI
https://observatorio.fm.usp.br/handle/OPI/293
Referências
  1. Agirre X, 2008, MOL CANCER RES, V6, P1830, DOI 10.1158/1541-7786.MCR-08-0167
  2. Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
  3. Bessiere D, 2008, J BIOL CHEM, V283, P4352, DOI 10.1074/jbc.M707537200
  4. Borden LS, 2005, CURR OPIN ONCOL, V17, P275, DOI 10.1097/01.cco.0000156985.47984.9e
  5. Catto JWF, 2009, CANCER RES, V69, P8472, DOI 10.1158/0008-5472.CAN-09-0744
  6. Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570
  7. Esrig E, 1994, NEW ENGL J MED, V331, P1259
  8. Foley NH, 2011, CELL DEATH DIFFER, V18, P1089, DOI 10.1038/cdd.2010.172
  9. Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894
  10. Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
  11. Huang HR, 2010, J BIOL CHEM, V285, P9383, DOI 10.1074/jbc.M109.095612
  12. Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705
  13. Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
  14. Lebanony D, 2009, J CLIN ONCOL, V27, P2030, DOI 10.1200/JCO.2008.19.4134
  15. Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P533, DOI 10.1016/j.urolonc.2009.05.008
  16. Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
  17. Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
  18. Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
  19. Neely LA, 2008, UROL ONCOL, V28, P39
  20. Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001
  21. Pandith AA, UROL ONCOL
  22. Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
  23. van Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421
  24. Veerla S, INT J CANC, V124, P2236
  25. Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065
  26. Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
  27. Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18
  28. Wu XR, 2009, CANCER METAST REV, V28, P281, DOI 10.1007/s10555-009-9189-4

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55